Book Image

The Future of Finance with ChatGPT and Power BI

By : James Bryant, Aloke Mukherjee
2.5 (4)
Book Image

The Future of Finance with ChatGPT and Power BI

2.5 (4)
By: James Bryant, Aloke Mukherjee

Overview of this book

In today's rapidly evolving economic landscape, the combination of finance, analytics, and artificial intelligence (AI) heralds a new era of decision-making. Finance and data analytics along with AI can no longer be seen as separate disciplines and professionals have to be comfortable in both in order to be successful. This book combines finance concepts, visualizations through Power BI and the application of AI and ChatGPT to provide a more holistic perspective. After a brief introduction to finance and Power BI, you will begin with Tesla's data-driven financial tactics before moving to John Deere's AgTech strides, all through the lens of AI. Salesforce's adaptation to the AI revolution offers profound insights, while Moderna's navigation through the biotech frontier during the pandemic showcases the agility of AI-focused companies. Learn from Silicon Valley Bank's demise, and prepare for CrowdStrike's defensive maneuvers against cyber threats. With each chapter, you'll gain mastery over new investing ideas, Power BI tools, and integrate ChatGPT into your workflows. This book is an indispensable ally for anyone looking to thrive in the financial sector. By the end of this book, you'll be able to transform your approach to investing and trading by blending AI-driven analysis, data visualization, and real-world applications.
Table of Contents (13 chapters)
Free Chapter
1
Part 1: From Financial Fundamentals to Frontier Tech: Navigating the New Paradigms of Data, EVs, and AgTech
6
Part 2: Pioneers and Protectors: AI Transformations in Software, Finance, Biotech, and Cybersecurity

Moderna’s mRNA odyssey and the transformation of biomedicine

Moderna, founded in 2010 and headquartered in Cambridge, Massachusetts, has emerged as a leading force in biotechnology with its innovative focus on mRNA-based therapies. Leveraging synthetic mRNA, Moderna instructs patients’ cells to produce proteins, laying the groundwork for therapies to prevent, treat, or cure diseases. The rapid validation of Moderna’s mRNA technology with its COVID-19 vaccine, authorized in December 2020, has brought global attention to this revolutionary approach.

We want to use focused subsections to break down complex topics into digestible pieces, covering everything from Moderna’s pivotal role in the COVID-19 pandemic to its broader applications and innovative strategies. This matters to you because understanding Moderna’s approach can offer valuable insights into investment opportunities, risk assessment, and financial reporting in the rapidly evolving biotech...